Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors

October 8th 2024

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

October 8th 2024

Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

October 7th 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

Neoadjuvant Pertuzumab Biosimilar Plus Trastuzumab/Docetaxel Meets pCR End Point in HER2+ Breast Cancer

October 7th 2024

HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.

FDA Approves Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

October 3rd 2024

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Neoantigen-Directed GRANITE Immunotherapy Improves PFS as Maintenance in MSS mCRC

October 2nd 2024

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

FDA Grants Priority Review to T-DXd in HR+, HER2-Low/-Ultralow Breast Cancer

October 1st 2024

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma

October 1st 2024

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML

September 30th 2024

Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.

Mirvetuximab Soravtansine Gains Traction in Heavily Pretreated FRα+ Platinum-Sensitive Ovarian Cancer

September 29th 2024

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.

Zelenectide Pevedotin Shows Early Promise as Less Toxic Alternative to Standard Regimens in Bladder Cancer

September 27th 2024

Terence Friedlander, MD, spotlights emerging agents of interest in advanced bladder cancer, including the Nectin-4–targeted therapy zelenectide pevedotin.

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors

September 27th 2024

The MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers.

Dendritic Cell–Based Immunotherapy Data in Resected Pancreatic Cancer Published in JCO

September 27th 2024

MesoPher cell therapy led to a 2-year recurrence-free survival rate of 64% and low-grade AEs in resected pancreatic cancer following chemotherapy.

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

September 26th 2024

Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.

Fixed-Dose Favezelimab Combo Fails to Improve OS in Pretreated, PD-L1+, MSS mCRC

September 25th 2024

The combination of favezelimab and pembrolizumab failed to improve OS vs regorafenib or TAS-102 in pretreated patients with PD-L1–positive, MSS mCRC.

AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning

September 23rd 2024

Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the examination of scans, and more.

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

September 19th 2024

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

NCCN Guideline Updates Expand IO/TKI Options and Precision Medicine Approaches in RCC

September 18th 2024

Moshe Ornstein, MD, MA, discusses the implications of updates to NCCN guidelines for the management of non–clear cell and clear cell renal cell carcinoma